1. Feldman H och Gracon S. I: Gauthier S, ed. Clinical Diagnosis and Management of
Alzheimer‘s Disease. Martin Dunitz: London; 1996:239-259.
2. Welsh KA, et al. A detection and staging of dementia in Alzheimer’s disease. Use of
neuropsychological measure developed for the Consortium to Establish a Registry for
Alzheimer’s disease. Arch Neurol. 1992;49:448-452.
3. Galasko D. An integrated approach to the management of Alzheimer’s disease:
assessing cognition, function and behaviour. Eur J Neurol. 1998;5(suppl 4):S9–17.
5. Sarazin M, et al. Neuropsychological predictors of dependency in patients with
Alzheimer’s disease. Neurology. 2005;64:1027-31.
6. Amieva H, et al. Prodromal Alzheimer’s disease: progressive emergence of the
clinical symptoms. Ann Neurol .2008;64:492-8.
7. Terry RD. Alzheimer’s disease and the aging brain. J Geriatr Psychiatry Neurol.
2006;19:125-128.
8. Scheff SW, et al. Hippocampal synaptic loss in early Alzheimer’s disease and mild
cognitive impairment. Neurobiol Aging. 2006;27:1372-1384.
9. Sperling RA, et al. Toward defining the preclinical stages of Alzheimer’s disease:
recommendations from the National Institute on Aging-Alzheimer’s Association
workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement.
2011;7:280-292.
10. Terry RD, et al. Physical basis of cognitive alterations in Alzheimer’s disease:
Synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991;30:572-580.
11. Kamphuis PJ och Scheltens P. Can nutrients prevent or delay onset of Alzheimer’s
disease? J Alzheimers Dis. 2010;20:765-775.
12. Glasø M, et al. Reduced concentrations of several vitamins in normal weight patients
with late-onset dementia of the Alzheimer type without vascular disease. J Nutr Health
Aging 2004;8:407-413.
13. Köseoglu E och Karaman Y. Relations between homocysteine, folate and vitamin B12
in vascular dementia and in Alzheimer disease. Clin Biochem. 2007;40:859-863.
14. Polidori MC, et al. Plasma antioxidant status, immunoglobulin g oxidation and lipid
peroxidation in demented patients: relevance to Alzheimer disease and vascular
dementia. Dement Geriatr Cogn Disord. 2004;18:265-270.
15. Conquer JA, et al. Fatty acid analysis of blood plasma of patients with Alzheimer’s
disease, other types of dementia, and cognitive impairment. Lipids. 2000;35:1305-1312.
16. Ravaglia G, et al. Plasma amino acid concentrations in patients with amnestic mild
cognitive impairment or Alzheimer disease. Am J Clin Nutr.2004;80:483-488.
17. Corrigan FM, et al. Tin and fatty acids in dementia. Prostaglandins Leukot Essent
Fatty Acids. 1991;43:229-238.
18. Corrigan FM, et al. Abnormal content of n-6 and n-3 long-chain unsaturated fatty
acids in the phosphoglycerides and cholesterol esters of parahippocampal cortex from
Alzheimer’s disease patients and its relationship to acetyl CoA content. Int J Biochem
Cell Biol. 1998;30:197-207.
19. Sijben JWC, et al. A multi nutrient concept to enhance synapse formation and
function: science behind a medical food for Alzheimer’s disease. OCL . 2011;18:267-270.
20. Sijben JWC, et al. Nutritional intervention with Fortasyn Connect: beneficial effects
in experimental models of Alzheimer’s pathology and functional decline. EFNS
2012.P1019
21. Astarita G, et al. Deficient liver biosynthesis of docosahexaenoic acid correlates with
cognitive impairment in Alzheimer’s disease. PLoS One. 2010;5:e12538.
22. Lopes Da Silva S, et al. Plasma nutrient status of Alzheimer’s disease patients
compared to cognitive intact elderly controls: A systematic review and metaanalysis.
European Geriatric Medicine. 2012;3:85.
23. Goodenowe DB, et al. Peripheral ethanolamine plasmalogen deficiency: a logical
causative factor in Alzheimer’s disease and dementia. J Lipid Res. 2007;48:2485-498.
24. Van Dam F och Van Gool WA. Hyperhomocysteinemia and Alzheimer’s disease: A
systematic review. Arch Gerontol Geriatr. 2009;48:425-430.
25. Yi JJ och Ehlers MD. Ubiquitin and protein turnover in synapse function. Neuron.
2005;47:629-632.
26. Kennedy EP och Weiss SB. The function of cytidine coenzymes in the biosynthesis
of phospholipides. J Biol Chem. 1956;222:193-214.
27. Wurtman RJ, et al. Synaptic proteins and phospholipids are increased in gerbil brain
by administering uridine plus docosahexaenoic acid orally. Brain Res. 2006;1088:83-92.
28. Cansev M, et al. Restorative effects of uridine plus docosahexaenoic acid in a rat
model of Parkinson’s disease. Neurosci Res. 2008;62:206-209.
29. Sakamoto T, et al. Oral supplementation with docosahexaenoic acid and uridine-5′-
monophosphate increases dendritic spine density in adult gerbil hippocampus. Brain
Res. 2007;1182:50-59.
30. Holguin S, et al. Chronic administration of DHA and UMP improves the impaired
memory of environmentally impoverished rats. Behav Brain Res. 2008;191:11-16.
31. Holguin S, et al. Dietary uridine enhances the improvement in learning and memory
produced by administering DHA to gerbils. FASEB J. 2008;22:3938-3946.
32. Cansev M, et al. Giving uridine and/or docosahexaenoic acid orally to rat dams
during gestation and nursing increases synaptic elements in brains of weanling pups.
Dev Neurosci. 2009;31:181-192.
33. Cansev M och Wurtman RJ. Chronic administration of docosahexaenoic acid or
eicosapentaenoic acid, but not arachidonic acid, alone or in combination with uridine,
increases brain phosphatide and synaptic protein levels in gerbils. Neuroscience.
2007;148:421-431.
34. Wang L, et al. Dietary supplementation with uridine-5′-monophosphate (UMP), a
membrane phosphatide precursor, increases acetylcholine level and release in striatum
of aged rat. Brain Res. 2007;1133:42-48.
35. Richardson UI, et al. Stimulation of CDP-choline synthesis by uridine or cytidine in
PC12 rat pheochromocytoma cells. Brain Res. 2003;971:161-167.
36. Richardson UI och Wurtman RJ. Polyunsaturated fatty acids stimulate
phosphatidylcholine synthesis in PC12 cells. Biochim Biophys Acta. 2007;1771:558-563.
37. van Wijk N, et al. Plasma choline concentration varies with different dietary levels of
vitamins B6, B12 and folic acid in rats maintained on choline-adequate diets. Br J
Nutr. 2012;107:1408-12.
38. Pooler AM, et al. Uridine enhances neurite outgrowth in nerve growth factordifferentiated
PC12. Neuroscience. 2005;134:207-214.
39. Scheltens P, et al. Efficacy of a medical food in mild Alzheimer’s disease: A
randomized, controlled trial. Alzheimers Dement. 2010;6:1-10.e1.
40. Scheltens P, et al. Efficacy of Souvenaid in mild Alzheimer’s disease: results from a
randomized, controlled trial. J Alzheimer’s Dis. 2012;31:225–236.